Partnering
Industrial Partnership Agreements
Biomunex ambition: to establish collaborations and partnerships with major industrial partners.
2019
Out-licensing agreement with SANOFI focused on generation and optimization of bi- and multi-specific antibody therapeutics.
Under this agreement, SANOFI has access to a part of BIOMUNEX’ technology for the generation, optimization, and development of bi- and multi-specific therapeutic antibodies.
To date, BIOMUNEX has received a significant upfront payment that has allowed it to pursue its development. BIOMUNEX is also eligible for clinical, regulatory, and commercial development milestones, while SANOFI will be responsible for research, development, manufacturing and commercialization activities worldwide.
2021
Worldwide out-licensing and co-development agreement with ONWARD Therapeutics for one of proprietary bispecific antibody programs of BIOMUNEX.
This collaboration covers the preclinical and clinical co-development of the antibody for the treatment of selected solid tumors and hematological malignancies.
BIOMUNEX has already received an upfront payment, but also the first clinical milestone thanks to the start of the Phase 1, and a strategic investment from ONWARD Therapeutics. BIOMUNEX is also eligible for clinical, regulatory, and commercial development milestones and royalties, as well as other payments.
2024
Global licensing agreement with IPSEN for the development of a first-in-class MAIT cell engager in immune-oncology.
This collaboration covers the development of BMX-502, a bispecific antibody capable of engaging and activating MAIT cells to target the GPC3 tumor antigen, a clinically validated target highly expressed across several types of cancers, to kill cancer cells.
Under the terms of this agreement, Biomunex will complete the IND-enabling package while Ipsen will assume responsibility for Phase I preparation activities, including submission of the Investigational New Drug (IND) application, and all subsequent clinical development and global commercialization activities.
Partnering
Biomunex is eligible to receive up to $610 million, including upfront, contingent upon successful development, regulatory and commercial milestones, in addition to tiered global royalties on sales.
